The U.S. Centers for Disease Control and Prevention, CDC, Atlanta, GA 30333, USA.
Eur J Clin Microbiol Infect Dis. 2013 Jun;32(6):735-43. doi: 10.1007/s10096-012-1798-0. Epub 2012 Dec 22.
The purpose of this study was to assess the performance of Cepheid® Xpert MTB/RIF® ("Xpert") and TB-Biochip® MDR ("TB-Biochip"). Sputum specimens from adults with presumptive tuberculosis (TB) were homogenized and split for: (1) direct Xpert and microscopy, and (2) concentration for Xpert, microscopy, culture [Lowenstein-Jensen (LJ) solid media and Mycobacteria Growth Indicator Tube® (MGIT)], indirect drug susceptibility testing (DST) using the absolute concentration method and MGIT, and TB-Biochip. In total, 109 of 238 (45.8 %) specimens were culture-positive for Mycobacterium tuberculosis complex (MTBC), and, of these, 67 isolates were rifampicin resistant (RIF-R) by phenotypic DST and 64/67 (95.5 %) were isoniazid resistant (INH-R). Compared to culture of the same specimen, a single direct Xpert was more sensitive for detecting MTBC [95.3 %, 95 % confidence interval (CI), 90.0-98.3 %] than direct (59.6 %, 95 % CI, 50.2-68.5 %) or concentrated smear (85.3 %, 95 % CI, 77.7-91.1 %) or LJ culture (80.8 %, 95 % CI, 72.4-87.5 %); the specificity was 86.0 % (95 % CI, 78.9-91.3 %). Compared with MGIT DST, Xpert correctly identified 98.2 % (95 % CI, 91.5-99.9 %) of RIF-R and 95.5 % (95 % CI, 85.8-99.2 %) of RIF-susceptible (RIF-S) specimens. In a subset of 104 specimens, the sensitivity of TB-Biochip for MTBC detection compared to culture was 97.3 % (95 % CI, 91.0-99.5 %); the specificity was 78.1 % (95 % CI, 61.5-89.9 %). TB-Biochip correctly identified 100 % (95 % CI, 94.2-100 %) of RIF-R, 94.7 % (95 % CI, 76.7-99.7 %) of RIF-S, 98.2 % (95 % CI, 91.4-99.9 %) of INH-R, and 78.6 % (95 % CI, 52.1-94.2 %) of INH-S specimens compared to MGIT DST. Xpert and Biochip were similar in accuracy for detecting MTBC and RIF resistance compared to conventional culture methods.
本研究旨在评估 Cepheid® Xpert MTB/RIF®(“Xpert”)和 TB-Biochip® MDR(“TB-Biochip”)的性能。将成人疑似肺结核(TB)的痰液标本进行匀浆和分割,用于:(1)直接 Xpert 和显微镜检查,以及(2)浓缩用于 Xpert、显微镜检查、培养[Lowenstein-Jensen(LJ)固体培养基和分枝杆菌生长指示管®(MGIT)]、间接药物敏感性测试(DST)使用绝对浓度法和 MGIT,以及 TB-Biochip。总共,238 份标本中有 109 份(45.8%)培养出结核分枝杆菌复合群(MTBC),其中,67 株分离株对利福平耐药(RIF-R),表型 DST 和 64/67(95.5%)异烟肼耐药(INH-R)。与相同标本的培养相比,单次直接 Xpert 检测 MTBC 的敏感性更高[95.3%,95%置信区间(CI),90.0-98.3%],高于直接(59.6%,95%CI,50.2-68.5%)或浓缩涂片(85.3%,95%CI,77.7-91.1%)或 LJ 培养(80.8%,95%CI,72.4-87.5%);特异性为 86.0%(95%CI,78.9-91.3%)。与 MGIT DST 相比,Xpert 正确识别了 98.2%(95%CI,91.5-99.9%)的 RIF-R 和 95.5%(95%CI,85.8-99.2%)的 RIF-S 标本。在 104 份标本的一个亚组中,TB-Biochip 检测 MTBC 的敏感性与培养相比为 97.3%(95%CI,91.0-99.5%);特异性为 78.1%(95%CI,61.5-89.9%)。TB-Biochip 正确识别了 100%(95%CI,94.2-100%)的 RIF-R、94.7%(95%CI,76.7-99.7%)的 RIF-S、98.2%(95%CI,91.4-99.9%)的 INH-R 和 78.6%(95%CI,52.1-94.2%)的 INH-S 标本,与 MGIT DST 相比。与传统培养方法相比,Xpert 和 Biochip 在检测 MTBC 和 RIF 耐药方面的准确性相似。